Therefore, Nirogacestat ic50 PLK-1 can be thought of as a potential target for preventing cervical carcinoma. Conflict of interests The authors declare that they have no competing interests. Acknowledgements This study was supported by grants from the National Natural Science Foundation of China (No. 30801225). References 1. Zhao EF, Bao L, Li C, Song L, Li YL: Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years. Di Yi Jun Yi Da Xue Xue Bao 2005, 25: 605–9.PubMed 2. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT,
Heintz AP, Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet 2003, 83: S41–78.CrossRef 3. Chen H, Yue J, Yang S, Ding H, Zhao R, Zhang S: Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res 2009, 28: 43.CrossRefPubMed 4. Yu C, Zhang X, Sun G, Guo X, Li H, You Y, Jacobs JL, Gardner K, Yuan D, Xu Z, Du D, Dai C, Stattic solubility dmso Qian Z, Jiang K, Zhu Y, Li QQ, Miao Y: RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med 2008, 12: 2334–49.CrossRefPubMed
5. Liu X, Erikson RL: Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003, 100: 5789–94.CrossRefPubMed 6. Liu L, Zhang M, Zou P: Polo-like kinase 1 as Dapagliflozin a new target for non-Hodgkin’s lymphoma treatment. Oncology 2008, 74: 96–103.CrossRefPubMed
7. Takaki T, Trenz K, Costanzo V, Petronczki M: Polo-like kinase 1 reaches beyond mitosis–cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008, 20: 650–60.CrossRefPubMed 8. Dai W, Wang Q, Traganos F: Polo-like kinases and centrosome regulation. Oncogene 2002, 21: 6195–200.CrossRefPubMed 9. Lane HA, Nigg EA: Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996, 135: 1701–13.CrossRefPubMed 10. Takai N, Hamanaka R, Yoshimatsu J, MDV3100 chemical structure Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene 2005, 24: 287–91.CrossRefPubMed 11. Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006, 6: 321–30.CrossRefPubMed 12. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I: Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001, 169: 41–9.CrossRefPubMed 13. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I: Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001, 164: 41–9.CrossRefPubMed 14. Huang XM, Dai CB, Mou ZL, Wang LJ, Wen WP, Lin SG, Xu G, Li HB: Overproduction of Cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: Implication for therapy. Can Lett 2009, 279: 47–56.CrossRef 15.